The National Comprehensive Cancer Network (NCCN) just released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate Cancer guidelines on November 7th, 2024 (Version 2.2025) You read that right – they have now added “prostate” to the name as well as the relevant content! Prostate cancer specific testing and risk management information is now centralized …
Permanent link to this article: https://inheritedcancer.net/post110824/
Did you know that men can get breast cancer too? In fact, Beyonce’s father, Matthew Knowles, was diagnosed with breast cancer in October 2019 and was found to have a BRCA2 mutation. Matthew’s children have a 50/50 chance of inheriting his BRCA2 mutation. Men with an inherited BRCA2 mutation are at an increased risk for …
Permanent link to this article: https://inheritedcancer.net/post100724/
A new study found that males with a BRCA2 mutation and metastatic hormone-sensitive prostate cancer face poorer outcomes. BRCA2 carriers were also found to have a higher risk of progression to castration-resistant prostate cancer. These findings highlight the importance of evaluating germline mutations among prostate cancer patients. Custodio-Cabello, et al. Urol Oncol. 2024;42(10):331.e13-331.e24. PMID: 38926076. …
Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2024-brca2-associated-prostate-cancer/
A new study found that men with a BRCA2 mutation and metastatic hormone-sensitive prostate cancer face poorer outcomes. BRCA2 carriers were also found to have a higher risk of progression to castration-resistant prostate cancer. These findings highlight the importance of evaluating germline mutations among prostate cancer patients. Learn more by reading the full article at: …
Permanent link to this article: https://inheritedcancer.net/post93024/
Below is a featured video from the September 2024 case conference, during which Ros Eeles, PhD, FRCP, FRCR, FMedSci discusses the genetic predisposition to prostate cancer and its relevance to targeted screening.
Permanent link to this article: https://inheritedcancer.net/video091224/
New studies to guide treatment strategies in men with prostate cancer and a BRCA mutation were recently published. Specifically, a recent study suggested that platinum-based chemotherapy may be as effective as PARP inhibitors for individuals with BRCA-positive metastatic castration-resistant prostate cancer.1 The study sheds light on treatment options for advanced prostate cancer patients. More recently, …
Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2024-brca-associated-prostate-cancer-treatment-updates/
A recent study found that Olaparib (Lynparza) improved survival outcomes among men with BRCA1/2 mutations and metastatic castration-resistant prostate cancer, regardless of whether the mutation was germline or somatic. This underscores the potential of targeted therapies in improving outcomes for those with inherited cancer gene mutations. Learn more at: https://ascopubs.org/doi/10.1200/JCO.23.00339 Reference: Mateo, et al. J …
Permanent link to this article: https://inheritedcancer.net/post22024/
A recent study suggests that Platinum Chemotherapy is as effective as PARP inhibitors for individuals with BRCA-positive metastatic castration-resistant prostate cancer. The study sheds light on treatment options for advanced prostate cancer patients 🩺✨ Learn more at: http://tinyurl.com/3vs2mk8f Reference: Fazekas, et al. Eur Urol Oncol. 2023: S2588-9311(23)00174-8. PMID: 37722977.
Permanent link to this article: https://inheritedcancer.net/post10324/
A new study found that inherited BRCA2, ATM, and NBN genes were most strongly associated with aggressive or metastatic prostate cancer. Learn more at: https://jamanetwork.com/journals/jamaoncology/article-abstract/2809874 Reference: Darst, et al. JAMA Oncol. 2023. PMID: 37733366.
Permanent link to this article: https://inheritedcancer.net/post110923/
On April 28th, 2023, the FDA approved olaparib plus abiraterone acetate for first line treatment for metastatic castration-resistant prostate cancer, but only in patients whose tumors have BRCA mutations. Although a broad indication for the combination therapy was desired, concerns about the trial design were raised, and the phase III results did not explicitly show …
Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-brca-associated-prostate-cancers/
A new study of almost 18,000 men with prostate cancer showed that inherited mutations in the BRCA2, ATM, and NBN genes were strongly associated with aggressive prostate cancer. Less strong associations were seen for inherited mutations in the MSH2, XRCC2, and MRE11A genes. The findings of this study suggest that knowing about inherited genes that …
Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-genes-associated-with-aggressive-prostate-cancer/
The National Comprehensive Cancer Network (NCCN) just released updated Genetic/Familial Breast, Ovarian, and Pancreatic Cancer guidelines on August 28th, 2023, which included: You can check out the full guidelines by creating a FREE account at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf
Permanent link to this article: https://inheritedcancer.net/post82923/
A critical step forward in cancer care! The FDA has approved the use of niraparib and abiraterone acetate with prednisone in treating patients with BRCA-mutated castration-resistant prostate cancer. The green light comes backed by the robust efficacy data from the MAGNITUDE trial. Read more about the FDA approval at https://tinyurl.com/dzdvtm9m Learn more about the MAGNITUDE …
Permanent link to this article: https://inheritedcancer.net/post82423/
Olaparib plus abiraterone acetate is recommended as the first line treatment for metastatic castration-resistant prostate cancer, but only in patients whose tumors have BRCA mutations. Although a broad indication for the combination therapy was desired, concerns about the trial design were raised, and the phase III results did not explicitly show that patients without a …
Permanent link to this article: https://inheritedcancer.net/post61623/
A study that compared a PARP inhibitor (talazoparib) to the standard of care (an androgen receptor inhibitor) in metastatic castration-resistant prostate cancer found that it improved progression-free survival regardless of BRCA mutation status. However, the benefit was greatest in males with a BRCA or other DNA repair gene mutation. Read the full article at this …
Permanent link to this article: https://inheritedcancer.net/post50823/
Researchers identified 9 new genetic variants that may increase the risk of developing prostate cancer. This study highlights the importance of studying diverse populations. Read the full article at this link: https://www.sciencedirect.com/science/article/abs/pii/S0302283823025617 Reference:Chen et al. Eur Urol. 2023;S0302-2838(23)02561-7. PMID: 36872133.
Permanent link to this article: https://inheritedcancer.net/post42223/
A study that evaluated a PARP inhibitor (niraparib) in males with metastatic prostate cancer found that those with a BRCA1 or BRCA2 mutation lived longer on average than those who did not have a BRCA mutation. Read the full article at the link: https://pubmed.ncbi.nlm.nih.gov/35131040/Reference:Smith et al. Lancet Oncol. 2022;23(3):362-373. PMID: 35131040.
Permanent link to this article: https://inheritedcancer.net/post42023/
In 1997 when I was a junior in college, my mom called to let me know that my father had been diagnosed with prostate cancer. Luckily for him, Prostate Specific Antigen (PSA) testing had recently started which resulted in early detection and subsequent prostatectomy. Due to his diagnosis and knowing prostate cancer is an inherited …
Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023span-stylecolor-56b0e4community-spotlight/
A study to test niraparib (a PARP inhibitor) in males with metastatic prostate cancer showed that those with an inherited BRCA1 or BRCA2 (BRCA) mutation lived longer on average compared to those without a BRCA mutation. Side effects from niraparib were similar to those previously reported with PARP inhibitors.1 Another PARP inhibitor trial tested an …
Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023prostate-cancer-treatment-updates/
A recent international study found that male BRCA1 and BRCA2 carriers have a higher risk for breast, pancreatic, and stomach cancer. Additionally, male BRCA2 carriers were found to have higher risks for prostate cancer. See the below table for the specific risk levels: Li et al. J Clin Oncol. 2022 Jan. PMID: 35077220. Social media …
Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-brca1-2-and-male-cancer-risks/
A new study suggests men with certain MSH2 and MSH6 mutations have higher risks of prostate cancer and may be candidates for PSA screening. Bancroft et al. Lancet Oncol. 2021 Nov. PMID: 34678156. Social media postDecember 17th, 2021. Available at: https://tinyurl.com/post121721
Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-lynch-syndrome-and-prostate-cancer/
Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2021-ask-the-expert/
A new Polish study based on two specific founder mutations in PALB2 reported that mutations in this gene may predispose to an aggressive, lethal form of prostate cancer.1 The investigators studied PALB2 prostate cancer risks, characteristics, and outcomes in almost 5,500 men with prostate cancer and compared them to over 8,000 cancer-free adults from Poland. …
Permanent link to this article: https://inheritedcancer.net/newsletter-fall-2021-prostate-cancer-and-palb2/
A recent study found that pathogenic variants in the Ataxia Telangiectasia Mutated (ATM) gene are associated with multiple cancers. Specifically, moderate-to-high risks for pancreatic, prostate, gastric, and invasive ductal breast cancers, and low-to-moderate risks for ductal carcinoma in situ, male breast cancer, ovarian cancer, colorectal cancer, and melanoma.This provides more data to guide risks and …
Permanent link to this article: https://inheritedcancer.net/post62122/
Read the full article for more information!https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00017-1/fulltextReference: Thiery-Vuillemin, et al. Lancet Oncol. 2022 Mar;23(3):393-405. PMID: 35157830.
Permanent link to this article: https://inheritedcancer.net/post40822/
A new study found that male BRCA1/2 carriers have a higher risk for breast, pancreatic, and stomach cancer. Additionally, male BRCA2 carriers were found to have higher risks for prostate cancer. Read the full Journal of Clinical Oncology article to learn more!https://ascopubs.org/doi/full/10.1200/JCO.21.02112Reference: Li et al. J Clin Oncol. 2022 Jan 25;JCO2102112. PMID: 35077220.
Permanent link to this article: https://inheritedcancer.net/post12822/
In every ICARE newsletter we give our participants the opportunity to have a question addressed by an expert in the field. In the latest edition, Dr. Kerry Schaffer discusses the use of PARP inhibitors to treat inherited forms of prostate cancer.Check out Dr. Schaffer’s full response at 👇https://inheritedcancer.net/newsletters/
Permanent link to this article: https://inheritedcancer.net/post122821/
A new study suggests men with MSH2 and MSH6 mutations have a higher incidence of prostate cancer, and may be candidates for PSA screening. Read the full article to learn more 👇 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00522-2/fulltext Reference: Bancroft et al. Lancet Oncol. 2021 Nov;22(11):1618-1631. PMID: 34678156.
Permanent link to this article: https://inheritedcancer.net/post121721/
Below you may watch a featured video from the August 2021 Genetics Case Conference, which focused on inherited prostate cancer with guest expert Kerry Schaffer, MD from Vanderbilt University Medical Center in Nashville, TN.
Permanent link to this article: https://inheritedcancer.net/video81221/
For more information, read the article available at: https://www.nature.com/articles/s41416-021-01410-0
Permanent link to this article: https://inheritedcancer.net/post70221/
Below you may watch a featured video from the June 2021 Genetics Case Conference, which focused on PALB2 with guest experts Marc Tischkowitz, MD, PhD from the University of Cambridge in Cambridge, England and Steven Narod, MD, FRCPC, FRSC from the Women’s College Research Institute in Toronto, Canada.
Permanent link to this article: https://inheritedcancer.net/video61021/
Permanent link to this article: https://inheritedcancer.net/1nlw2021/
Permanent link to this article: https://inheritedcancer.net/video100820/
For further information, view the article available at: https://ascopubs.org/doi/full/10.1200/JCO.20.01035
Permanent link to this article: https://inheritedcancer.net/post91820/
The National Comprehensive Cancer Network (NCCN) released new guidelines on September 8th, 2020, which included updates to genetic testing criteria by cancer type as follows: Breast Cancer: Broadened to include relatives with ALL grades of prostate cancer (not just high-grade) Now having multiple breast cancer diagnoses is NOT dependent on whether the diagnoses were …
Permanent link to this article: https://inheritedcancer.net/post91520/
There continue to be ongoing advances in treatment studies among those with inherited cancer gene mutations, which are rapidly being followed by FDA approval for specific cancer treatments. Select studies and advances are summarized below: BRCA1/2 Carriers: Breast Cancer: For those with later stage or metastatic breast cancer, the FDA currently has approvals for the use …
Permanent link to this article: https://inheritedcancer.net/2nls2020/
Over 600,000 men age 40 and older who were part of a family with at least three consecutive generations affected with prostate cancer were studied from the Utah Population Database. Findings from this study showed that: 36,000 had prostate cancer (5.9%) 2,500 had early-onset disease (7%) 4,000 had lethal disease (11.1%) 15,000 had clinically significant …
Permanent link to this article: https://inheritedcancer.net/post81420/
On May 19, 2020 the FDA approved the use of olaparib (Lynparza) as treatment in BRCA and other gene carriers (homologous recombination repair genes) with metastatic castration-resistant prostate cancer who have been treated with enzalutamide or abiraterone. Link to full article: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer
Permanent link to this article: https://inheritedcancer.net/post52220/
On May 15, 2020 the FDA approved the use of rucaparib (Rubraca) as treatment in BRCA carriers with metastatic castration-resistant prostate cancer who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Link to full article: https://www.fda.gov/drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate
Permanent link to this article: https://inheritedcancer.net/post51920/
Findings from a recent study showed that olaparib (PARP inhibitor) significantly improved progression-free survival in patients with BRCA1, BRCA2, or ATM genetic alterations. Benefits were also more broadly seen among patients with homologous recombination repair gene defects. Link to full article: https://www.nejm.org/doi/full/10.1056/NEJMoa1911440 Check out the ASCO post article at: https://www.ascopost.com/news/may-2020/olaparib-for-patients-with-mcrpc-and-homologous-recombination-repair-gene-alterations/
Permanent link to this article: https://inheritedcancer.net/post50620/
A recent study reported a high complete response rate among men with a BRCA1/2 mutation with metastatic, castration-resistant prostate cancer who were treated with niraparib (a PARP inhibitor) of 63% compared to 17% in the non-BRCA1/2 group.1 Based on this data, the Federal Drug Administration (FDA) granted breakthrough therapy designation to niraparib on October 3, …
Permanent link to this article: https://inheritedcancer.net/3nlw2020/
There were significant updates and restructuring of the guidelines, with some highlights included below: Substantial reorganization of the guidelines as follows: Now organized by organ site, rather than primarily by certain high penetrance genes Focused efforts to simplify genetic testing criteria Only one flow diagram included, to outline the ‘genetic testing process’ Following scenarios now …
Permanent link to this article: https://inheritedcancer.net/1nlw2020/
A worldwide study reporting on cancer risks among individuals with mutations in Lynch syndrome genes showed that there are substantial differences in cancer risks across the various genes.1 Specifically, the risk for colorectal cancer in those with MLH1, MSH2, and MSH6 mutations was substantially higher than what was seen for those with PMS2 mutations. Additionally, …
Permanent link to this article: https://inheritedcancer.net/5nlw2020/
A worldwide study suggests that risks for cancers for the various Lynch syndrome genes have some differences. The risk of colorectal cancer for those with a mutation in the MLH1, MSH2 and MSH6 genes is higher than what is seen for carriers of a PMS2 mutation. Additionally, men with MSH2 gene mutations have a higher …
Permanent link to this article: https://inheritedcancer.net/post2720/
The FDA granted breakthrough therapy designation to niraparib (a PARP inhibitor) for the treatment of men with BRCA1/2 positive, metastatic castration-resistant, and heavily pre-treated prostate cancer. Results from a recent study show a 63% complete response rate in men with BRCA1/2 positive, metastatic castration-resistant prostate cancer treated with niraparib compared to 17% in the non- …
Permanent link to this article: https://inheritedcancer.net/post122019/
We are excited to share the latest version of the NCCN Genetic/Familial Breast, Ovarian and Pancreatic Guidelines (V1.2020), which were just updated. Some of the changes made include: PALB2 was added as a high penetrance gene (similar to BRCA1, BRCA2, CDH1, PTEN and TP53) It is appropriate to consider risk reducing mastectomy for cancer risk management …
Permanent link to this article: https://inheritedcancer.net/post12419/
There is now information to suggest that identifying inherited mutations in DNA repair genes, such as BRCA1/2 and other genes, in men with metastatic prostate cancer may open doors for other treatment options. Results of a phase 2 clinical trial among men with metastatic and heavily pre-treated prostate cancer were presented at the American Society …
Permanent link to this article: https://inheritedcancer.net/2nls2019/
Treatment among patients with metastatic castration-resistant prostate cancer: A PARP inhibitor (rucaparib) was granted a breakthrough therapy designation in October 2018 for monotherapy (i.e., sole treatment) among men with metastatic castration-resistant prostate cancer (with a BRCA1/2 mutation) who have received at least one prior androgen receptor-directed treatment and taxane-based chemotherapy. This designation was granted based …
Permanent link to this article: https://inheritedcancer.net/3nlw2019/
A recent study reported that a large proportion of men with aggressive prostate cancer have inherited cancer gene mutations. Specifically, among 400 patients with castration-resistant prostate cancer, 16.2% had a germline mutation in a DNA damage repair gene, including 3% with a BRCA2 mutation. Among BRCA2 carriers, survival was 17.4 months, which was much lower …
Permanent link to this article: https://inheritedcancer.net/5nlw2019/
Findings through a recent study reported that inherited cancer gene mutations were present in 8.2% of those with advanced or metastatic prostate cancer, which provides additional support to include this group of men in broader testing, particularly as targeted treatments based on inherited gene mutations becomes increasingly available.1 Another recent study suggested that those with …
Permanent link to this article: https://inheritedcancer.net/10nlw2018/
Among 799 patients with prostate cancer, the rate of BRCA1/2 mutations was much higher among those who passed away of prostate cancer (6.07%) compared to those with low risk disease (1.44%).1 Among the group that died of prostate cancer, those with BRCA1/2 or ATM mutations passed away at an earlier age and had a shorter …
Permanent link to this article: https://inheritedcancer.net/3nlw2017/
Several prior studies have suggested that men with a BRCA mutation (primarily BRCA2) tend to develop an aggressive form of prostate cancer that is more likely to metastasize. These findings were recently extended through a new study published in the New England Journal of Medicine.1 In this study, almost 700 men with metastatic prostate cancer, …
Permanent link to this article: https://inheritedcancer.net/5nls2016/
A recent study published in the New England Journal of Medicine suggests that PARP-Inhibitors may be of potential use in men who are no longer responding to standard treatments and carry either somatic (i.e., tumor) and/or germline (inherited) mutations in DNA-repair genes (i.e., BRCA1/2, ATM, Fanconi Anemia genes and CHEK2).1 Of 49 men with prostate …
Permanent link to this article: https://inheritedcancer.net/4nlw2016/
Over the last few years, there have been studies to suggest that men with Lynch Syndrome may have a higher risk for developing prostate cancer.1,2,3,4,5 The results of these studies have differed as to whether there is an association with an aggressive form of disease. For example, some studies report the risk of developing prostate …
Permanent link to this article: https://inheritedcancer.net/6nls2014/
Over the last few years, there have been a number of studies to suggest that men with BRCA mutations, particularly BRCA2, have a higher risk of developing aggressive prostate cancer. It remains uncertain whether these men might benefit from screening through the prostate-specific antigen (PSA) test. Within the last few years, PSA screening guidelines in …
Permanent link to this article: https://inheritedcancer.net/1nls2014/
Over the last few years, a number of studies have suggested that men with germline BRCA mutations (especially BRCA2) have poorer outcomes when they develop prostate cancer. In fact, a recent study of 2019 patients with prostate cancer, including 18 BRCA1 carriers, 61 BRCA2 carriers, and 1940 noncarriers indicated that germline mutations were more frequently …
Permanent link to this article: https://inheritedcancer.net/3nls2013/
Over the last few years, there have been several studies that suggest that men with BRCA mutations are at a higher risk for developing and dying from aggressive prostate cancer. It is possible that PSA testing may be of benefit in men with BRCA mutations. However, until the utility of PSA is determined in these …
Permanent link to this article: https://inheritedcancer.net/2nls2012/
